MX2023004807A - Composiciones y metodos para el tratamiento de la celiaquia. - Google Patents

Composiciones y metodos para el tratamiento de la celiaquia.

Info

Publication number
MX2023004807A
MX2023004807A MX2023004807A MX2023004807A MX2023004807A MX 2023004807 A MX2023004807 A MX 2023004807A MX 2023004807 A MX2023004807 A MX 2023004807A MX 2023004807 A MX2023004807 A MX 2023004807A MX 2023004807 A MX2023004807 A MX 2023004807A
Authority
MX
Mexico
Prior art keywords
methods
compositions
celiacia
treatment
celiac
Prior art date
Application number
MX2023004807A
Other languages
English (en)
Spanish (es)
Inventor
Lance Stewart
Clancey Wolf
David Baker
Ingrid Swanson Pultz
Justin Bloomfield Siegel
Christine Elaine Tinberg
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2023004807A publication Critical patent/MX2023004807A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023004807A 2020-10-30 2021-10-29 Composiciones y metodos para el tratamiento de la celiaquia. MX2023004807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108163P 2020-10-30 2020-10-30
PCT/US2021/057197 WO2022094177A1 (en) 2020-10-30 2021-10-29 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
MX2023004807A true MX2023004807A (es) 2023-05-10

Family

ID=78819631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004807A MX2023004807A (es) 2020-10-30 2021-10-29 Composiciones y metodos para el tratamiento de la celiaquia.

Country Status (12)

Country Link
US (1) US20250064903A1 (https=)
EP (1) EP4237554A1 (https=)
JP (1) JP2023548083A (https=)
KR (1) KR20230093323A (https=)
CN (1) CN116829166A (https=)
AR (1) AR123961A1 (https=)
AU (1) AU2021368118A1 (https=)
CA (1) CA3195929A1 (https=)
CO (1) CO2023006731A2 (https=)
MX (1) MX2023004807A (https=)
TW (1) TW202233834A (https=)
WO (1) WO2022094177A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4475707B2 (ja) * 1998-10-05 2010-06-09 武田薬品工業株式会社 N末端メチオニンの除去方法
CA2882502A1 (en) 2011-08-10 2013-02-14 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
NZ737500A (en) * 2015-06-08 2025-02-28 Univ Washington Compositions and methods for treating celiac sprue disease
AU2017380106B2 (en) * 2016-12-22 2024-05-09 Ew Nutrition Gmbh Stable protease variants

Also Published As

Publication number Publication date
EP4237554A1 (en) 2023-09-06
AU2021368118A9 (en) 2023-07-06
CA3195929A1 (en) 2022-05-05
TW202233834A (zh) 2022-09-01
AR123961A1 (es) 2023-01-25
US20250064903A1 (en) 2025-02-27
AU2021368118A1 (en) 2023-05-11
JP2023548083A (ja) 2023-11-15
WO2022094177A1 (en) 2022-05-05
CN116829166A (zh) 2023-09-29
KR20230093323A (ko) 2023-06-27
CO2023006731A2 (es) 2023-06-09

Similar Documents

Publication Publication Date Title
CL2024000411A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
ECSP22083174A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
ECSP21082195A (es) Formas sólidas de un inhibidor de glyt1
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
BR112018010669A8 (pt) anticorpo anti-pcsk9 e utilização do mesmo
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo
CO2025012422A2 (es) Inhibidores de quinasa dependientes de ciclina (cdk2)
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
CO2023006731A2 (es) Composiciones y métodos para el tratamiento de la celiaquía
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
MX2021015501A (es) Anticuerpos y metodos de uso.
CO2023016037A2 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos